Key Concepts
Mood Stabilizers and Anxiolytics Overview
Mood Stabilizers: | Drug | Use | Key Monitoring | |---|---|---| | Lithium | Bipolar disorder (gold standard) | Serum level (narrow TI); renal function; thyroid | | Valproate (Depakote) | Bipolar, epilepsy | LFTs; CBC; drug level; teratogenicity | | Lamotrigine (Lamictal) | Bipolar depression maintenance | Rash (SJS); slow titration | | Carbamazepine (Tegretol) | Bipolar, epilepsy | CBC; Na+ (SIADH); drug level | Anxiolytics: | Drug | Class | Key Points | |---|---|---| | Diazepam, lorazepam, alprazolam | Benzodiazepines | Rapid effect; dependence/tolerance; CNS depression | | Buspirone (BuSpar) | Non-benzodiazepine | No dependence; delayed onset (2–4 weeks); first-line for GAD | | Hydroxyzine (Vistaril) | Antihistamine | Sedating; no dependence; used PRN | On the exam, writers often pair stable-sounding options with unstable data—notice the mismatch before you commit. If the stem names a license or role, reread that line; scope errors are classic trap answers even when the clinical topic is familiar. Run a 60-second scan: breathing work and oxygenation, perfusion and end organs, neuro baseline, likely infection sources, and devices that can fail quietly.
